A woman came to see me two years ago holding a printout from a forum, genuinely upset. Her sister, in another state, was on Wegovy. She had been given Ozempic. She had spent a week convinced her doctor had fobbed her off with the cheap version.
They were on the same drug.
The same molecule, two labels
Semaglutide is a GLP-1 receptor agonist. Novo Nordisk sells it under three names in the United States — Ozempic and Wegovy as weekly injections, Rybelsus as a daily tablet — and the pens differ in dose ceiling and in the words printed on the box.
| Ozempic | Wegovy | |
|---|---|---|
| Active drug | Semaglutide | Semaglutide |
| FDA-approved for | Type 2 diabetes; cardiovascular risk reduction in type 2 diabetes | Chronic weight management; cardiovascular risk reduction in established CVD with overweight or obesity |
| Dose range | 0.25 → 2.0 mg weekly | 0.25 → 2.4 mg weekly |
| Typical coverage path | Diabetes benefit | Weight-management benefit, where one exists |
That is the entire difference. There is no secret formulation, no different filler, no “weight loss version” of the molecule.
Why the label decides everything
American insurance does not pay for drugs. It pays for indications.
Most commercial plans cover type 2 diabetes as a matter of course. A very large share of the same plans explicitly exclude drugs used for weight loss — language that in many cases has sat in the plan document since the 1990s, long before anyone had a medication that worked well enough for the exclusion to matter.
So the practical logic in the exam room usually runs like this:
- You have type 2 diabetes. Ozempic is on-label, covered, and cheap for you. This is the easy case.
- You have obesity and your plan has a weight-management benefit. Wegovy is on-label and the prior authorization is winnable.
- You have obesity and your plan excludes weight-loss drugs. Nothing is covered. This is where people end up paying cash, appealing, or going to a compounder.
- You have obesity plus a qualifying cardiovascular history. Since the SELECT results, Wegovy has an approved cardiovascular indication in people with established heart disease and overweight or obesity — which for some patients is a genuinely different coverage conversation, and one almost nobody knows to ask about.
Does the 0.4 mg matter?
A little. In the pivotal trial of semaglutide 2.4 mg in adults with overweight or obesity, mean weight reduction was around 15 percent at 68 weeks — substantially more than placebo, and higher than what is typically seen at the diabetes doses.
But dose response in this class is not a cliff. Plenty of people do very well at 1.0 or 1.7 mg and never need the top of the ladder. Some people cannot tolerate the top of the ladder at all. The maximum dose is a ceiling, not a target, and the reflex to climb to it because it exists is one of the more common errors I see.
The best dose is the lowest one that is still doing the job. That is true of thyroid hormone, it is true of blood pressure medication, and it is true here.
The thing that actually goes wrong
The failure mode I see most often is not someone getting the “wrong” brand. It is someone getting a prescription for a drug their plan will never pay for, discovering that at the pharmacy counter, and going home with nothing.
Ask two questions before you leave the appointment:
- Which product is being prescribed, and what diagnosis code is going on the claim?
- Has anyone checked whether my plan covers that combination?
Most practices can run a benefits check in under a minute. Almost nobody offers unless asked.
Write down which product you were given and at what dose, in something you will still have in a year. This sounds patronising until you meet the number of people who genuinely cannot say whether they are on Ozempic or Wegovy, or at what strength — which becomes a real problem when a pharmacy substitutes, a plan changes, or a clinician needs to know where on the ladder you actually sit. Zenday keeps it, and so does a photograph of the box.
The version of this that made me angry
The woman with the forum printout had been on Ozempic for eleven weeks. She had lost about eighteen pounds. She was, by any clinical measure, doing well — and she had spent seven days feeling cheated because a website with an affiliate relationship had told her that Wegovy was “the real one.”
Nothing about her care changed after our conversation. She stayed on the same pen at the same dose. She just stopped believing she was getting a lesser version of something, which turned out to be the more useful intervention that week.